Applications for San Francisco (Batch 12) extended through September 15th, 2021!

Learn more about investing in Circularis

Our team will get back to you soon to follow up on your inquiry.
Circularis
Enhancing gene expression for therapy and synthetic biology
Founded
2014
Employees*
1-10
Funding to Date*
undisclosed
Website
circularisbiotech.com
Mat Falkowski, CEO
If we can control gene expression with high accuracy in specific cell types, then we can use gene therapy to fix specific cells in the human body that are not working correctly
Codon optimization can get you up to 10-fold yield increase, but promoters can potentially give 100,000-fold.

Circularis’s technology screens a huge library of promoters in a single cell. Through directed evolution selection, the strongest promoters rise to the top and can be identified and incorporated into a host of gene expression applications, such as biomanufacturing and gene therapy. Beyond just promoters, their technology also works for enhancers, silencers/repressers, stability sequences, and nuclear delivery sequences. The process happens within days, instead of months.

Similar Companies

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.